Expanded hemodialysis was noninferior to online hemodiafiltration when assessing risks for all-cause mortality and major CV events, according to study data presented at the European Renal Association Congress in Glasgow, Scotland.
Previous studies have shown that online hemodiafiltration was associated with better patient survival compared with expanded hemodialysis, according to Patricia de Sequera Ortiz, MD, PhD, chief of nephrology at University Hospital Infanta Leonor in Madrid and Full Professor at the Universidad Complutense de Madrid. However, both approaches for middle-molecule

ORLANDO — Patients with critical illness experience specific trajectories of depression, PTSD and functional disability after discharge from the ICU, according to data presented at the American Thoracic Society International Conference.
“Psychological and functional challenges are quite common after critical illness,” Mark Rolfsen, MD, MSCI, clinical and T32 research fellow, division of allergy, pulmonary and critical care medicine, Vanderbilt Health, said during his presentation.
Approximately one in five patients develop PTSD related to ICU admission, he said, one in three develop new or

New patients without malignancy symptoms who sought skin cancer checks at an academic dermatology clinic often had few or no risk factors for a skin cancer diagnosis, according to a study.
Of the 4,875 patients who completed a dermatology previsit survey for a skin cancer check, 22% reported having no specific skin concern, according to the study published in JAMA Dermatology. Most of these patients had almost no risk factors for malignancy, with more than half being 50 years or younger and only 17.3% reporting a personal history of skin cancer, the data showed.
“This study is important because

NEW ORLEANS — Individuals with obesity and autoimmune diseases who use a GLP-1 receptor agonist may have lower risk for mortality, fewer cardiovascular and thrombotic events and lower health care utilization, researchers reported.
Among adults with obesity and at least one autoimmune disease, those who used a GLP-1 had a 44% lower risk for all-cause mortality, 31% lower risk for pulmonary embolism, 21% lower risk for ED visits and 17% lower risk for venous thromboembolism compared with those who did not use a GLP-1, according to data presented at the American Diabetes Association Scientific

Click here to read the Healio Exclusive, “Rising rate of ocular allergies calls for collaborative, eco-conscious interventions.”
The most common forms of ocular allergy are seasonal allergic conjunctivitis and perennial allergic conjunctivitis. They can be annoying and negatively affect quality of life but are not sight-threatening.
Both are ocular hypersensitivity disorders caused by exposure to an allergen trigger and mediated by immunoglobulin E. Seasonal allergic conjunctivitis (SAC) is worse for most in the spring and fall, and perennial allergic conjunctivitis (PAC) lasts all year long.

Heart rhythm monitoring in the weeks before cardioversion therapy for atrial fibrillation/atrial flutter reduced the frequency of same-day procedure cancellations, researchers reported.
The researchers posited that automated ambulatory precardioversion rhythm monitoring via smartphone photoplethysmography could streamline health care resources allocated to this patient population, according to findings published in JAMA Cardiology.
“Simple daily rhythm monitoring with smartphone-based photoplethysmography before cardioversion is feasible and can markedly reduce same-day cancellations,

NEW ORLEANS —Adults with type 2 diabetes receiving once-daily orforglipron alongside insulin glargine had greater improvements in HbA1c than those receiving placebo, according to data from the ACHIEVE-5 trial.
As Healio previously reported, the FDA approved orforglipron (Foundayo, Eli Lilly) in April for the treatment of overweight or obesity. The oral medication is also under development for the treatment of type 2 diabetes and, in the ACHIEVE-1 trial, orforglipron reduced HbA1c and body weight among adults with type 2 diabetes compared with placebo. In new findings from the ACHIEVE-5 trial

Adults with migraine whose previous preventive therapy had failed saw improvements in cognitive symptoms with 12 months of eptinezumab, according to a poster presented at the American Headache Society 68th Annual Scientific Meeting.
Eptinezumab (Vypeti; Lundbeck) targets calcitonin gene-related peptides (CGRPs) to prevent episodic and chronic migraine, according to Richard B. Lipton, MD, Edwin S. Lowe Chair in Neurology at Albert Einstein College of Medicine, and colleagues.
“One of the most exciting things that has happened in migraine ever is the advent of CGRP-targeted therapies,” Lipton

CHICAGO — In this video, Michael J. Morris, MD, FASCO, discusses results of the phase 2 CONVERGE-01 trial evaluating an alpha-emitting radioantibody for patients with metastatic castration-resistant prostate cancer.
Treatment effects also included a decline in prostate-specific antigen.
Findings from the study, which assessed the safety and efficacy of Ac-225 rosopatamab tetraxetan (CONV01-alpha, Convergent Therapeutics), were presented at ASCO Annual Meeting.
“In terms of future work, this is going to go into phase 3,” Morris, medical oncologist and prostate cancer section head at Memorial

CHICAGO — In this video, Shimoli Barot, MD, discusses a study that showed a genomic test could be used to identify patients with clinically high-risk ER-positive, HER2-negative breast cancer who may be able to safely avoid chemotherapy.
These findings, from the phase 3 OPTIMA trial, were presented at ASCO Annual Meeting.
“I think this helps us inform the treatment decision that biology is a lot more important in understanding how we tailor our systemic adjuvant treatment options for these patients,” Barot, breast medical oncologist at Cleveland Clinic, told Healio.